VolitionRx Completes $1.21M Registered Direct Offering

In August, Stradling represented VolitionRx, a company which, through its subsidiaries, is developing and commercializing simple, easy-to-use, costeffective blood tests to diagnose and monitor a range of diseases, including some cancers, diseases associated with NETosis and sepsis, with a registered
direct offering of Common Stock and Warrants to Purchase Common Stock to new investors and insider investors, for gross proceeds to the Company of approximately $1.21 Million and potential future gross proceeds to the Company of an additional $1.332 Million upon the exercise of Warrants, if fully exercised.